Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. | Riding a regulatory win for its base editing ...
On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in vivo gene editing. In vivo refers to studies or experiments conducted on living organisms or cells ...
Good morning, everyone, and thank you for joining Editas Medicine webinar to unveil our lead development candidate, EDIT-401. This webinar is being recorded and can be accessed in the future through ...
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 is an experimental, potentially transformative in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly ...
Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results